Literature DB >> 29097143

Glycoprotein Non-Metastatic Melanoma Protein B (GPNMB) and Cancer: A Novel Potential Therapeutic Target.

Manisha Taya1, Stephen R Hammes2.   

Abstract

Glycoprotein non-metastatic melanoma protein B (GPNMB) is a transmembrane protein enriched on the cell surface of cancer cells, including melanoma, glioblastoma, and triple-negative breast cancer. There is growing evidence identifying GPNMB as a tumor-promoter; however, despite its biological and clinical significance, the molecular mechanisms engaged by GPNMB to promote tumorigenesis are not well understood. GPNMB promotes aggressive behaviors such as tumor cell proliferation, migration, and invasion. The extracellular domain of GPNMB shed from the cell surface interacts with integrins to facilitate in the recruitment of immune-suppressive and pro-angiogenic cells to the tumor microenvironment, thereby enhancing tumor migration and invasion. GPNMB also modulates receptor tyrosine kinases and integrin signaling in a cell autonomous fashion, leading to downstream kinase signaling that in turn triggers the expression and secretion of tumorigenic factors such as matrix metalloproteinases (MMPs) and cytokines. Therefore, GPNMB exerts its pro-tumorigenic role both intracellularly and in a paracrine fashion through shedding its extracellular domain. This review highlights the importance of GPNMB in cancer progression and discusses molecular mediators of GPNMB-induced tumor growth and invasion.
Copyright © 2017. Published by Elsevier Inc.

Entities:  

Keywords:  Antibody-drug conjugate; Breast cancer; GPNMB; Invasion; Matrix metalloproteinase; Melanoma

Mesh:

Substances:

Year:  2017        PMID: 29097143      PMCID: PMC6166407          DOI: 10.1016/j.steroids.2017.10.013

Source DB:  PubMed          Journal:  Steroids        ISSN: 0039-128X            Impact factor:   2.668


  51 in total

1.  The melanoma-associated transmembrane glycoprotein Gpnmb controls trafficking of cellular debris for degradation and is essential for tissue repair.

Authors:  Bing Li; Ana P Castano; Thomas E Hudson; Brian T Nowlin; Shuei-Liong Lin; Joseph V Bonventre; Kenneth D Swanson; Jeremy S Duffield
Journal:  FASEB J       Date:  2010-08-13       Impact factor: 5.191

Review 2.  Arming antibodies: prospects and challenges for immunoconjugates.

Authors:  Anna M Wu; Peter D Senter
Journal:  Nat Biotechnol       Date:  2005-09       Impact factor: 54.908

3.  DC-HIL is a negative regulator of T lymphocyte activation.

Authors:  Jin-Sung Chung; Kota Sato; Irene I Dougherty; Ponciano D Cruz; Kiyoshi Ariizumi
Journal:  Blood       Date:  2007-02-06       Impact factor: 22.113

4.  Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer.

Authors:  Johanna Bendell; Mansoor Saleh; April A N Rose; Peter M Siegel; Lowell Hart; Surendra Sirpal; Suzanne Jones; Jennifer Green; Elizabeth Crowley; Ronit Simantov; Tibor Keler; Thomas Davis; Linda Vahdat
Journal:  J Clin Oncol       Date:  2014-09-29       Impact factor: 44.544

Review 5.  Targeting GPNMB with glembatumumab vedotin: Current developments and future opportunities for the treatment of cancer.

Authors:  April A N Rose; Marco Biondini; Rafael Curiel; Peter M Siegel
Journal:  Pharmacol Ther       Date:  2017-05-22       Impact factor: 12.310

6.  Osteoactivin bioinformatic analysis: prediction of novel functions, structural features, and modes of action.

Authors:  Abdulhafez A Selim
Journal:  Med Sci Monit       Date:  2009-02

7.  CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma.

Authors:  Kam Fai Tse; Michael Jeffers; Vincent A Pollack; Denise A McCabe; Melanie L Shadish; Nikolai V Khramtsov; Craig S Hackett; Suresh G Shenoy; Bing Kuang; Ferenc L Boldog; John R MacDougall; Luca Rastelli; John Herrmann; Michael Gallo; Gadi Gazit-Bornstein; Peter D Senter; Damon L Meyer; Henri S Lichenstein; William J LaRochelle
Journal:  Clin Cancer Res       Date:  2006-02-15       Impact factor: 12.531

Review 8.  Antibody-drug conjugates for cancer therapy.

Authors:  Paul J Carter; Peter D Senter
Journal:  Cancer J       Date:  2008 May-Jun       Impact factor: 3.360

9.  Osteoactivin, an anabolic factor that regulates osteoblast differentiation and function.

Authors:  Samir M Abdelmagid; Mary F Barbe; Mario C Rico; Sibel Salihoglu; Israel Arango-Hisijara; Abdul Hafez Selim; Michael G Anderson; Thomas A Owen; Steven N Popoff; Fayez F Safadi
Journal:  Exp Cell Res       Date:  2008-03-10       Impact factor: 3.905

10.  Osteoactivin (GPNMB) ectodomain protein promotes growth and invasive behavior of human lung cancer cells.

Authors:  Moses O Oyewumi; Dharani Manickavasagam; Kimberly Novak; Daniel Wehrung; Nikola Paulic; Fouad M Moussa; Gregory R Sondag; Fayez F Safadi
Journal:  Oncotarget       Date:  2016-03-22
View more
  21 in total

1.  TFE3 Xp11.2 Translocation Renal Cell Carcinoma Mouse Model Reveals Novel Therapeutic Targets and Identifies GPNMB as a Diagnostic Marker for Human Disease.

Authors:  Masaya Baba; Mitsuko Furuya; Takanobu Motoshima; Martin Lang; Shintaro Funasaki; Wenjuan Ma; Hong-Wei Sun; Hisashi Hasumi; Ying Huang; Ikuma Kato; Tsuyoshi Kadomatsu; Yorifumi Satou; Nicole Morris; Baktiar O Karim; Lilia Ileva; Joseph D Kalen; Luh Ade Wilan Krisna; Yukiko Hasumi; Aiko Sugiyama; Ryoma Kurahashi; Koshiro Nishimoto; Masafumi Oyama; Yoji Nagashima; Naoto Kuroda; Kimi Araki; Masatoshi Eto; Masahiro Yao; Tomomi Kamba; Toshio Suda; Yuichi Oike; Laura S Schmidt; W Marston Linehan
Journal:  Mol Cancer Res       Date:  2019-05-01       Impact factor: 5.852

2.  Comprehensive genomic analysis contrasting primary colorectal cancer and matched liver metastases.

Authors:  Akio Shiomi; Masatoshi Kusuhara; Takashi Sugino; Teiichi Sugiura; Keiichi Ohshima; Takeshi Nagashima; Kenichi Urakami; Masakuni Serizawa; Hideyuki Saya; Ken Yamaguchi
Journal:  Oncol Lett       Date:  2021-04-12       Impact factor: 2.967

3.  Downregulation of glycoprotein non-metastatic melanoma protein B prevents high glucose-induced angiogenesis in diabetic retinopathy.

Authors:  Tingyu Qin; Xiangying Xi; Zhipeng Wu
Journal:  Mol Cell Biochem       Date:  2022-08-29       Impact factor: 3.842

4.  Neutrophil elastase from myeloid cells promotes TSC2-null tumor growth.

Authors:  Manisha Taya; Maria de la Luz Garcia-Hernandez; Javier Rangel-Moreno; Briaunna Minor; Erin Gibbons; Stephen R Hammes
Journal:  Endocr Relat Cancer       Date:  2020-04       Impact factor: 5.678

5.  Blocking Monocytic Myeloid-Derived Suppressor Cell Function via Anti-DC-HIL/GPNMB Antibody Restores the In Vitro Integrity of T Cells from Cancer Patients.

Authors:  Masato Kobayashi; Jin-Sung Chung; Muhammad Beg; Yull Arriaga; Udit Verma; Kevin Courtney; John Mansour; Barbara Haley; Saad Khan; Yutaka Horiuchi; Vijay Ramani; David Harker; Purva Gopal; Farshid Araghizadeh; Ponciano D Cruz; Kiyoshi Ariizumi
Journal:  Clin Cancer Res       Date:  2018-07-26       Impact factor: 12.531

6.  Targeted sequencing of Parkinson's disease loci genes highlights SYT11, FGF20 and other associations.

Authors:  Uladzislau Rudakou; Eric Yu; Lynne Krohn; Jennifer A Ruskey; Farnaz Asayesh; Yves Dauvilliers; Dan Spiegelman; Lior Greenbaum; Stanley Fahn; Cheryl H Waters; Nicolas Dupré; Guy A Rouleau; Sharon Hassin-Baer; Edward A Fon; Roy N Alcalay; Ziv Gan-Or
Journal:  Brain       Date:  2021-03-03       Impact factor: 13.501

Review 7.  Considerations for the Nonclinical Safety Evaluation of Antibody-Drug Conjugates.

Authors:  J Edward Fisher
Journal:  Antibodies (Basel)       Date:  2021-04-19

Review 8.  The Role of GPNMB in Inflammation.

Authors:  Marina Saade; Giovanna Araujo de Souza; Cristoforo Scavone; Paula Fernanda Kinoshita
Journal:  Front Immunol       Date:  2021-05-12       Impact factor: 7.561

9.  Glycoprotein nonmetastatic melanoma protein B regulates lysosomal integrity and lifespan of senescent cells.

Authors:  Masayoshi Suda; Ippei Shimizu; Goro Katsuumi; Chieh Lun Hsiao; Yohko Yoshida; Naomi Matsumoto; Yutaka Yoshida; Akihiro Katayama; Jun Wada; Masahide Seki; Yutaka Suzuki; Shujiro Okuda; Kazuyuki Ozaki; Mayumi Nakanishi-Matsui; Tohru Minamino
Journal:  Sci Rep       Date:  2022-04-20       Impact factor: 4.996

10.  Role of the kringle-like domain in glycoprotein NMB for its tumorigenic potential.

Authors:  Rudy Xie; Yukari Okita; Yumu Ichikawa; Muhammad Ali Fikry; Kim Tuyen Huynh Dam; Sophie Thi PhuongDung Tran; Mitsuyasu Kato
Journal:  Cancer Sci       Date:  2019-06-26       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.